Qureshi Waseem, Dar Maqsood Ahmad, Rather Mohd Younis
Hospital Administration, Government Medical College, University of Kashmir, Jammu and Kashmir, Srinagar 190010, India.
Department of Medicine, Government Medical College, University of Kashmir, Jammu and Kashmir, Srinagar 190010, India.
World J Diabetes. 2024 Sep 15;15(9):1833-1836. doi: 10.4239/wjd.v15.i9.1833.
The gut microbiota is important in the development and progression of metabolic illnesses such type 2 diabetes, cardiovascular disease (CVD), and obesity. This diverse community of microorganisms controls a variety of physiological functions, including metabolism, inflammation, and immune response. Understanding these interactions has resulted in novel therapeutic options, including microbiome supplementation. The gut microbiome is extremely susceptible to dietary changes, which can alter its makeup and function, influencing metabolite synthesis that affects host health. Certain metabolites, such as butyrate and propionate, have been proven to protect against metabolic illnesses, whereas trimethylamine has been linked to CVD. Prebiotics, probiotics, synbiotics, and postbiotics are being investigated by researchers as ways to change the gut microbiome and boost metabolic health. Despite advances in therapy and lifestyle adjustments, the prevalence of metabolic syndrome is increasing, emphasizing the need for new medicines.
肠道微生物群在2型糖尿病、心血管疾病(CVD)和肥胖等代谢性疾病的发生和发展中起着重要作用。这个多样化的微生物群落控制着多种生理功能,包括新陈代谢、炎症和免疫反应。对这些相互作用的理解带来了新的治疗选择,包括微生物群补充。肠道微生物群极易受到饮食变化的影响,饮食变化会改变其组成和功能,影响影响宿主健康的代谢物合成。某些代谢物,如丁酸盐和丙酸盐,已被证明可以预防代谢性疾病,而三甲胺则与心血管疾病有关。研究人员正在研究益生元、益生菌、合生元和后生元,作为改变肠道微生物群和促进代谢健康的方法。尽管在治疗和生活方式调整方面取得了进展,但代谢综合征的患病率仍在上升,这凸显了对新药的需求。